Roche Stock Earnings Estimates Boosted by Erste Group Bank

Roche Holding AG (OTCMKTS:RHHBY) – Research analysts at Erste Group Bank raised their FY2026 EPS estimates for Roche in a research note issued on Wednesday, October 21st. Erste Group Bank analyst H. Engel now anticipates that the company will post earnings per share of $3.10 for the year, up from their previous estimate of $3.05. The consensus estimate for Roche’s current full-year earnings is $3.02 per share. Erste Group Bank also issued estimates for Roche’s FY2027 earnings at $3.36 EPS.

RHHBY has been the subject of several other research reports. Morgan Stanley raised Roche from an “equal weight” rating to an “overweight” rating and set a $63.00 target price for the company in a research note on Friday, August 7th. Deutsche Bank Aktiengesellschaft raised shares of Roche from a “hold” rating to a “buy” rating in a research note on Friday. Oddo Bhf raised shares of Roche to an “outperform” rating in a research note on Tuesday, October 20th. Royal Bank Of Canada began coverage on shares of Roche in a research report on Tuesday, September 8th. They issued an “outperform” rating on the stock. Finally, Zacks Research raised Roche from a “strong sell” rating to a “hold” rating in a report on Monday, August 24th. Eight equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $60.00.

Roche Price Performance

Shares of OTCMKTS:RHHBY opened at $60.37 on Wednesday. Roche has a 12 month low of $40.07 and a 12 month high of $61.49. The stock’s 50 day moving average price is $55.39 and its 200 day moving average price is $53.62.

Institutional Investors Weigh In On Roche

A number of institutional investors have recently modified their holdings of the stock. Woodstock Corp bought a new stake in shares of Roche in the 3rd quarter valued at approximately $245,000. GAMMA Investing LLC lifted its stake in Roche by 15.3% in the third quarter. GAMMA Investing LLC now owns 33,458 shares of the company’s stock valued at $1,736,000 after acquiring an additional 4,443 shares during the last quarter. Renasant Bank acquired a new stake in Roche in the second quarter valued at approximately $210,000. North Star Asset Management Inc. acquired a new stake in Roche in the second quarter valued at approximately $1,351,000. Finally, Puzo Michael J bought a new stake in Roche in the second quarter worth approximately $1,229,000.

About Roche

Roche Holding AG is a Switzerland-based healthcare company focused on pharmaceuticals and diagnostics. Founded in 1896 and headquartered in Basel, Roche develops medicines and diagnostic technologies intended to support the prevention, diagnosis and treatment of serious diseases.

The company’s pharmaceutical business concentrates on areas including oncology, immunology, neuroscience, ophthalmology and hematology. Its products include targeted cancer therapies, treatments for multiple sclerosis and hemophilia, and medicines for other specialized conditions.